Stock Movers Deere Falls, Veris Residential Climbs, Vanda Pharmaceuticals Surges as FDA Approves Bipolar, Schizophrenia Drug
Feb 23, 2026
Markets react to a bleak outlook for the farm economy after a major downgrade hits an agricultural giant. A residential real estate firm agrees to an all-cash buyout at a set price, sparking a big pop. A pharma company sees shares surge after regulatory approval for an oral treatment for bipolar I and schizophrenia.
AI Snips
Chapters
Transcript
Episode notes
Deere Downgrade Cites Elusive Farm Rebound
- Jefferies downgraded Deere to underperform, arguing the stock already prices in a farm-economy rebound that may be elusive.
- Analyst Stephen Volkmann warns troughs can last years as farmers face high costs and volatile trade, justifying profit-taking on a 40% YTD gain.
Veris Residential Agreed To $19 Per Share Takeover
- Veris Residential agreed to an all-cash $19 per share acquisition by an investor consortium led by Affinius Capital and Vista Hill Partners.
- The $1.7 billion REIT's shares jumped double digits, marking its best day since July 2023.
Vanda Stocks Jump After FDA Approval
- Vanda Pharmaceuticals surged after FDA approval of an oral drug for manic or mixed episodes in bipolar I disorder and schizophrenia in adults.
- The tiny ~$59 million market-cap biotech saw shares rally as much as ~45%, trading up about 40% intraday.